Dr Barbara Golotta and colleagues performed a large prospective multicentre cohort study to improve knowledge of therapy for chronic hepatitis C in real clinical practice.
The researchers examined a diverse population of adults with chronic hepatitis C including patients with comorbid conditions, laboratory abnormalities and demographic features who were under-represented or excluded from peginterferon registration studies was treated with peginterferon α-2a (40 kDa) or α-2b (12 kDa) plus ribavirin at the investigator’s discretion.
During the study, 5399 treatment-naive patients received peginterferon α-2a or peginterferon α-2b.
|Overall sustained virological response rate was 57%|
|European Journal of Gastroenterology & Hepatology|
The team found that sustained virological response rate was 57% overall, 60% in patients without CSP, and 53% in patients with CSP.
The researchers found that significant predictors of sustained virological response included hepatitis C virus genotype 2 or 3 infection, absence of cirrhosis, hepatitis C virus RNA≤500 000 IU/ml, alanine transaminase quotient >3× the upper limit of normal, age ≤65 years, BMI<25 kg/m2, at least 80% of the planned exposure to peginterferon and ribavirin and prescription of peginterferon α-2a.
Dr Golotta and team comment, "The results provide detailed information on the outcome of therapy for chronic hepatitis C in a diverse Italian population that included a large number of patients with CSP, and provides an insight into the generalizability of the results obtained in the more restricted setting of randomized registration trials."